Transmission of HIV-1, development of persistent infection, and establishment of the prognostically-important plasma viral load setpoint, are the three critical events that sustain the HIV-1 pandemic and lead to the clinical sequelae of AIDS. A vaccine that favorably impacts any one of these key events could have a major impact on the HIV/AIDS pandemic; a practically achievable vaccine in the near term might impact all three, whereas an ideal vaccine would induce sterilizing immunity. Thus, we would propose that rational HIV-1 vaccine development requires an in-depth understanding of viral and host determinants of HIV-1 transmission, persistence, and partial containment in primary human infection. This should reveal critical viral vulnerabilities as well as host immune defense mechanisms amenable to vaccine-elicited augmentation. The Principal Investigator has thus developed a research plan that targets four essential aspects of viral-host interaction in acute and early infection in order to test the following overall hypothesis: HIV-1 leads to chronic persistent infection rather than acutely lethal disease because elements of the adaptive immune system partially constrain viral replication beginning in the earliest stages of primary infection. The goal of this project is not only to test rigorously this overarching hypothesis, but then to dissect and elucidate those viral and host factors that mediate this effect.
Aim 1. To elucidate the genetic, biologic, antigenic, and structural characteristics of sexually transmitted virus and mechanisms underlying virus transmission.
Aim 2. To elucidate the ontogeny of HIV-1 specific T cell, natural killer (NK) cell, and dendritic cell (DC) responses in acute and early HIV-1 Infection.
Aim 3. To elucidate the ontogeny of HIV-1 specific B cell responses in acute and early HIV-1 infection.
Aim 4. To elucidate host genetic differences affecting susceptibility to HIV-1 infection and disease progression in acute and early HIV-1 infection. Thus, each R01 aim addresses important scientific gaps in our understanding of early viral, immunologic, and host genetic influences on primary HIV-1 infection, thus providing critical information to drive HIV-1 vaccine development.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Song, Hongshuo; Giorgi, Elena E; Ganusov, Vitaly V et al. (2018) Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun 9:1928
Boelen, Lies; Debebe, Bisrat; Silveira, Marcos et al. (2018) Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1. Sci Immunol 3:
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Epi4K Consortium; EuroEPINOMICS-RES Consortium; Epilepsy Phenome Genome Project (2017) Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data. Eur J Hum Genet 25:894-899
Liu, Donglai; Wang, Chu; Hora, Bhavna et al. (2017) A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology 14:46
Pacheco, Beatriz; Alsahafi, Nirmin; Debbeche, Olfa et al. (2017) Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. J Virol 91:
Fouda, Genevieve G; Eudailey, Joshua; Kunz, Erika L et al. (2017) Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. Mucosal Immunol 10:228-237
Shen, Xiaoying; Bogers, Willy M; Yates, Nicole L et al. (2017) Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques. J Virol 91:
Fischetti, Lucia; Zhong, Ziyun; Pinder, Christopher L et al. (2017) The synergistic effects of combining TLR ligand based adjuvants on the cytokine response are dependent upon p38/JNK signalling. Cytokine 99:287-296
Gelfman, Sahar; Wang, Quanli; McSweeney, K Melodi et al. (2017) Annotating pathogenic non-coding variants in genic regions. Nat Commun 8:236

Showing the most recent 10 out of 395 publications